PACLITAXEL NEAPOLIS 150 MG BT 1
Ovarian Carcinoma: In first-line treatment of ovarian cancer in patients with advanced or residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin.
In second-line treatment of ovarian cancer in patients with metastatic ovarian carcinoma after failure of standard platinum-based treatment. Breast Carcinoma: In adjuvant treatment, paclitaxel is indicated for the treatment of breast carcinoma with lymph node invasion after a treatment with anthracycline and cyclophosphamide (AC).
The adjuvant treatment with paclitaxel should be considered as an alternative to a prolongation of the treatment with AC. PACLITAXEL NEAPOLIS is indicated in the initial treatment of locally advanced or metastatic breast cancer, either in combination with an anthracycline in patients for whom an anthracycline treatment is appropriate, or in combination with trastuzumab in patients with HER-2 overexpression classified 3+ by immunohistochemistry and for whom an anthracycline treatment is not appropriate.
Non-small cell lung carcinoma: PACLITAXEL NEAPOLIS is indicated in the treatment of non-small cell lung carcinoma in patients who are not eligible for surgery or radiotherapy, either in monotherapy, or in combination with cisplatin.
Kaposi's sarcoma: PACLITAXEL NEAPOLIS is indicated for the treatment of Kaposi's sarcoma in patients with advanced symptomatic HIV disease after failure of a previous treatment with liposomal anthracycline, in patients who cannot tolerate this treatment, or in patients for whom this treatment is not considered appropriate.
